Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 12;14:1251922. doi: 10.3389/fphar.2023.1251922

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Hernández-Mondragón, Hernández-Hernández, Crespo-Ramírez, Prospero-García, Rocha-Arrieta, Fuxe, Borroto-Escuela and Perez de la Mora.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of the co-administration of oxytocin and quinpirole into the central amygdala in the shock-probe burying test and of the locomotion in the open-field test. (A) Co-infusion of quinpirole (Quinp) (0.15 μg) + oxytocin (3 ng) evoked a marked decrease in the time that animals spent burying the probe of the test versus that of the control group. No effects on (B) the latency to the first episode of burying and (C) on the number of shocks that the rats received during the test were observed. (D) No significant differences in the locomotor activity of any treated group were observed as compared to the control. The Kruskal–Wallis test was followed by the Dunn test. *p < 0.05. Control: n = 15; quinpirole 0.15 µg/side: n = 9; oxytocin 3 ng/side: n = 13; quinpirole 0.15 µg + oxytocin 3 ng/side: n = 13.